This review provides practical strategies for the titration and selection of heart failure medications while navigating blood pressure targets in both normotensive and hypertensive patients.
This article briefly reviews the latest hypertension guidelines and how they should be individualised in patients with HF, including the two specific phenotypes: HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Key recent trials and guidelines show that HF medications remain beneficial and safe to use even in patients without overt hypertension, provided that they are tolerated. We also outline practical strategies for titration and selection of HF medications, most of which affect BP, in an outpatient setting. These strategies are applicable to both normotensive patients and those with pre-existing hypertension.
Helmy et al. (Wed,) studied this question.